Nektar Therapeutics posts $741.7M cash balance

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

Q: What cash and investments did NKTR report in its April 2026 8-K?

Q: As of what date does Nektar Therapeutics’ $741.7 million cash figure apply?

Q: Is the liquidity information in NKTR’s April 2026 8-K considered filed or furnished?

Q: Does the $741.7 million figure represent Nektar’s full financial position?

Q: What type of SEC filing did Nektar use to disclose its April 2026 cash balance?

8-K Event Classification

Key Figures

Key Terms

What cash and investments did NKTR report in its April 2026 8-K?

As of what date does Nektar Therapeutics’ $741.7 million cash figure apply?

Is the liquidity information in NKTR’s April 2026 8-K considered filed or furnished?

Does the $741.7 million figure represent Nektar’s full financial position?

What type of SEC filing did Nektar use to disclose its April 2026 cash balance?

Who signed the April 20, 2026 Nektar Therapeutics 8-K?

Nektar Therapeutics reported approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This is an estimated liquidity figure and not a complete presentation of the company’s overall financial condition or operating results.

The approximately $741.7 million in cash and investments in marketable securities applies as of April 1, 2026. Nektar notes this amount is based solely on information available as of the announcement date and does not represent full financial statements.

The liquidity information in Item 7.01 is being furnished, not filed, under the Exchange Act. As a result, it is not subject to Section 18 liability and is not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

No. Nektar states the $741.7 million cash and marketable securities figure is an estimate and not a comprehensive statement of its operating results or overall financial position as of April 1, 2026. Detailed results would appear in separate periodic reports.

Nektar used a Form 8-K under Item 7.01 (Regulation FD) to disclose its estimated cash and investments. This form allows the company to share material informational updates with the market while treating them as furnished rather than filed information.

Nektar Therapeutics furnished an update on its liquidity position.

Accepted by SEC EDGAR 04/20/2026 - 04:58 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Nektar Therapeutics furnished an update on its liquidity position. The company reported having approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This figure is an estimate based on information available at that time and is not a full statement of operating results or overall financial position.

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Cash and investments in marketable securities: $741.7 million

1 metrics

Cash and investments in marketable securities $741.7 million As of April 1, 2026

Regulation FD, marketable securities, Emerging growth company, furnished

4 terms

Regulation FD regulatory

"Item 7.01. Regulation FD. On April 20, 2026, Nektar Therapeutics..."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

marketable securities financial

"approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026."

Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.

Emerging growth company regulatory

"Emerging growth company Item 7.01. Regulation FD."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

furnished regulatory

"The information contained in Item 7.01 ... is being furnished and shall not be deemed to be “filed”."

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Nektar Therapeutics reported approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This is an estimated liquidity figure and not a complete presentation of the company’s overall financial condition or operating results.

The approximately $741.7 million in cash and investments in marketable securities applies as of April 1, 2026. Nektar notes this amount is based solely on information available as of the announcement date and does not represent full financial statements.

The liquidity information in Item 7.01 is being furnished, not filed, under the Exchange Act. As a result, it is not subject to Section 18 liability and is not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

No. Nektar states the $741.7 million cash and marketable securities figure is an estimate and not a comprehensive statement of its operating results or overall financial position as of April 1, 2026. Detailed results would appear in separate periodic reports.

Nektar used a Form 8-K under Item 7.01 (Regulation FD) to disclose its estimated cash and investments. This form allows the company to share material informational updates with the market while treating them as furnished rather than filed information.

The April 20, 2026 Form 8-K for Nektar Therapeutics was signed on the company’s behalf by Elizabeth Zhang, who is identified as Vice President, Legal. Her signature indicates the report was duly authorized under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 20, 2026

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24006

94-3134940

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	NKTR	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD.

On April 20, 2026, Nektar Therapeutics (the “Company”) announced it had approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This announcement reflects the Company’s estimates based solely upon information available to it as of the date of the announcement, and the amounts reported are not a comprehensive statement of its operating results or financial position as of April 1, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

NEKTAR THERAPEUTICS

Date: April 20, 2026

/s/ Elizabeth Zhang

Elizabeth Zhang

Vice President, Legal

3 documents